scholarly journals A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US

2021 ◽  
Author(s):  
Yiling Jiang ◽  
Lori D. Bash ◽  
Leif Saager
Keyword(s):  
Neuromuscular Blockade ◽  
Impact Analysis ◽  
Hypothetical Cohort ◽  
Budgetary Impact ◽  
The Us

scholarly journals Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis

2010 ◽  
Vol 16 (1) ◽  
pp. 31-42 ◽  
Author(s):  
José Martínez-Raga ◽  
Francisco González Saiz ◽  
César Pascual ◽  
Miguel A. Casado ◽  
Francisco J. Sabater Torres
Keyword(s):  
Impact Analysis ◽  
Budgetary Impact ◽  
Opioid Treatment

scholarly journals Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213745 ◽  
Author(s):  
Eric A. Jones ◽  
Benjamin P. Linas ◽  
Ve Truong ◽  
James F. Burgess ◽  
Karen E. Lasser
Keyword(s):  
Primary Care ◽  
Hepatitis C ◽  
Treatment Program ◽  
Impact Analysis ◽  
Drug Pricing ◽  
Hepatitis C Treatment ◽  
Budgetary Impact ◽  
Program Effects

scholarly journals PSU18 BUDGET IMPACT ANALYSIS OF SUGAMMADEX ON NEUROMUSCULAR BLOCKADE REVERSAL IN COLOMBIA

2019 ◽  
Vol 22 ◽  
pp. S368
Author(s):  
P. Lasalvia ◽  
D. Rosselli ◽  
F. Hernández ◽  
C. Beltran ◽  
M. Rojas ◽  
...  
Keyword(s):  
Neuromuscular Blockade ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Neuromuscular Blockade Reversal

scholarly journals Cost-effectiveness analysis and budgetary impact of antipsychotics available in the Brazilian Unified Health System

2020 ◽  
Vol 12 (3) ◽  
pp. 195-205
Author(s):  
Cid Manso de Mello Vianna ◽  
◽  
Ricardo Ribeiro Alves Fernandes ◽  
Gabriela Bittencourt Gonzalez Mosegui ◽  
Valéria Queiroz Pagnin ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Health System ◽  
Impact Analysis ◽  
Cost Effective ◽  
Lifetime Horizon ◽  
Budgetary Impact ◽  
Unified Health System ◽  
Cost Strategy ◽  
Schizophrenic Patients ◽  
Effective Choice

Objective: To carry out a cost-effectiveness and budget impact analysis of antipsychotic use in adults to treat schizophrenia from the perspective of the Unified Health System (SUS). Methods: A Markov model simulated the treatment of schizophrenic patients with an initial average age of 25 years and a lifetime horizon. The possibility of combining drugs resulted in 20 pharmacotherapeutic strategies. Results: The lowest-cost strategy, risperidone/olanzapine, obtained values of $45,092.77 with effectiveness of 15.97 QALY. The incremental cost-effectiveness ratio in dollars/QALY of olanzapine/risperidone was 2,470.24, and risperidone/ziprasidone was 352,671.90, compared to the first option. All other therapeutic combinations were dominated. The budgetary impact assessment indicated that the most cost-effective choice could generate savings of US$ 1,555.00 on average, per patient, over five years. Conclusion: The therapeutic proposal with the lowest cost per patient was risperidone combined with olanzapine, revealing these two drugs as a strategy with lower budgetary impact and better cost-effectiveness.

Sign in / Sign up

Export Citation Format

Share Document